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Interstitial lung disease caused by TS-1: a case of 
long-term drug retention as a fatal adverse reaction
Joong-Min Park, In Gyu Hwang
1, Suk-Won Suh, Kyong-Choun Chi
Departments of Surgery and 
1Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
TS-1 is an oral anti-cancer agent for gastric cancer with a high response rate and low toxicity. We report a case of long-term 
drug retention of TS-1 causing interstitial lung disease (ILD) as a fatal adverse reaction. A 65-year-old woman underwent a 
total gastrectomy with pathologic confirmation of gastric adenocarcinoma. She received 6 cycles of TS-1 and low-dose cispla-
tin for post-operative adjuvant chemotherapy followed by single-agent maintenance therapy with TS-1. After 8 months, the 
patient complained of a productive cough with sputum and mild dyspnea. A pulmonary evaluation revealed diffuse ILD in 
the lung fields, bilaterally. In spite of discontinuing chemotherapy and the administration of corticosteroids, the pulmonary 
symptoms did not improve, and the patient died of pulmonary failure. TS-1-induced ILD can be caused by long-term drug 
retention that alters the lung parenchyma irreversibly, the outcome of which can be life-threatening. Pulmonary evaluation 
for early detection of disease is recommended.
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INTRODUCTION
Gastric cancer remains one of the leading causes of can-
cer deaths worldwide. Complete surgical resection pro-
vides the only curative chance for gastric cancer. In spite of 
recent improvements in overall survival rates, the mortal-
ity of patients remains high because many patients are di-
agnosed in the advanced stages of gastric cancer [1]. In 
spite of many effective chemotherapeutic agents and vari-
ous administration methods, it has been shown that gas-
tric cancer is one of the malignant diseases that is less sen-
sitive to chemotherapy [2].
TS-1 is a novel, oral fluorouracil formation composed of 
tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and po-
tassium oxonate (Oxo) in a molar ratio 1:0.4:1, based on bi-
ochemical modulation of 5-fluorouracil [3]. Late phase II 
clinical trials have already been conducted in gastric can-
cer patients with a response rate of 44.6%. On the strength 
of such encouraging results, gastric cancer as an indication 
for the use of TS-1 was approved in March 1999. As TS-1 is 
effective when administered orally and has a low in-
cidence of severe adverse effects, TS-1 is expected to be 
suitable for outpatient chemotherapy [4].
We report the first case of long-term drug retention of 
TS-1 with a fatal adverse reaction causing interstitial lung 
disease (ILD).Interstitial lung disease caused by TS-1
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Fig. 1. Chest X-ray and 
chest computed tomo-
graphy scan showing 
reticular infiltration and 
ground glass opacities 
in both lower lung 
fields, suggesting dif-
fuse interstitial lung di-
sease, such as idiopathic 
pulmonary fibrosis or 
bronchiolitis obliterans 
with organizing pneu-
monia.
CASE REPORT
A 65-year-old woman visited our hospital on 29 April 
2008 for evaluation of intermittent epigastric pain which 
had developed 6 months earlier. The medical history was 
unremarkable. She has no past history of pulmonary dis-
ease and the chest X-ray was normal. Endoscopic evalua-
tion demonstrated a deep ulcerative lesion in the angle to 
the high body of the stomach; the biopsy revealed it as a 
poorly differentiated adenocarcinoma. An abdominopel-
vic computed tomography (CT) scan revealed a thicken-
ing of the gastric wall, adjacent fat infiltration, and multi-
ple metastatic lymph nodes around the left gastric artery, 
suggesting advanced gastric cancer.
The patient underwent total gastrectomy and splenec-
tomy with standard D2 lymph node dissection on 15 May 
2008. Macro- and microscopically, no residual tumor was 
remained (R0 resection). The pathologic results confirmed 
a stage IV (T3N3) gastric cancer according to the 6th edi-
tion of the American Joint Committee on Cancer/Interna-
tional Union Against Cancer tumor node metastasis 
classification. She was classified as an Eastern Cooperative 
Oncology Group performance status of 1 [5]. Based on her 
body surface area (1.52 m
2), combined chemotherapy with 
TS-1 capsules (50 mg twice daily after breakfast and sup-
per for 21 days) and intravenous cisplatin (60 mg on day 
8), followed by 2 drug-free weeks, was administered from 
the 10th post-operative day. After the termination of 6 cy-
cles of chemotherapy, there was no evidence of tumor re-
currence or drug-induced adverse effects. Therefore, sin-
gle-agent additional maintenance therapy with TS-1 (50 
mg twice daily after breakfast and supper for 4 weeks), 
with 2 weeks of a drug-free interval was continued since 12 
December 2008. During the period of administration of 
TS-1, physical examination and laboratory test were 
checked every month. Abnormal finding was not detected 
during this period. Eight months later, she complained of 
a productive cough with sputum and mild dyspnea on 7 
August 2009. The laboratory findings were within normal 
limits, including a negative sputum culture (gram stain 
and acid-fast bacillus culture). Fine crackles were audible 
on auscultation and a chest X-ray showed an interstitial 
shadow in the lower lung fields bilaterally (Fig. 1). The 
chest CT scan revealed diffuse ILD, such as idiopathic pul-
monary fibrosis or bronchiolitis obliterans with organiz-
ing pneumonia in the lung fields bilaterally (Fig. 1). 
Cessation of chemotherapy and the administration of cor-
ticosteroids relieved the patient’s symptoms mildly; how-
ever, the interstitial shadows persisted on chest X-rays 
without any improvement. Then, corticosteroid therapy 
was continued with daily 7.5 mg of prednisolone. On 15 
December 2009, a chest X-ray and CT scan was obtained Joong-Min Park, et al.
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Fig. 2. A chest X-ray 
showed increased inter-
stitial shadows in both 
lungs and a chest com-
puted tomography scan 
also revealed aggrava-
ted ground glass opaci-
ties and reticular ho-
neycomb lesions in both 
lower lung fields.
because of the patient’s worsening pulmonary symptoms 
and revealed progression of diffuse ILD (Fig. 2). In spite of 
the aggressive management in intensive care unit and the 
intravenous administration of corticosteroids with 125 mg 
of methylprednisolone, her symptoms did not improve. 
The pathologic organism was not verified by sputum mi-
crobiologic study. She died of pulmonary failure due to 
progression of interstitial pneumonia on 11 January 2010. 
An autopsy was not performed.
DISCUSSION
Instead of the conventional high-dose intravenous ad-
ministration that has as a goal of total cell killing, the con-
cept of how to continue drug administration safely for 
long periods and ultimately prolong survival without 
compromising quality of life is now the standard chemo-
therapeutic approach for gastric cancer. Thus, TS-1 could 
be an attractive anti-cancer agent for gastric cancer, with a 
high response rate and low toxicity. The possibility of out-
patient use of TS-1 has increased the convenience for both 
physicians and patients [3,4].
Several randomized trials have shown that TS-1 is an ex-
cellent oral anti-cancer drug for the treatment of advanced 
gastric cancer, and have suggested that this agent may be 
useful for neoadjuvant chemotherapy [6].
For outpatient chemotherapy, however, a low incidence 
of severe adverse reactions is especially important. The in-
cidence of grade III or IV adverse reactions of TS-1 in 449 
patients was ＜10% in phase II clinical trials, except for 
neutropenia (11.1%). The incidence of grade III or IV 
non-hematologic adverse reactions, stomatitis, nausea, 
vomiting, diarrhea and anorexia was low because of the 
Oxo contained in TS-1. Oxo is distributed in the gastro-
intestinal tract at a high concentration after oral admin-
istration, and alleviates gastrointestinal toxicity. Hand- 
foot syndrome, although not life-threatening, can severely 
disrupt the patient’s daily life; however, hand-foot syn-
drome was not observed because CDHP reduced the deg-
radation of 5 Flurouracil (5-FU) in the liver [3].
In the early post-operative period, patients have not re-
covered from surgical stress and the limitation of food in-
take due to gastrectomy itself could possibly exacerbate 
the adverse reactions, such as anorexia and nausea. Thus, 
a delay in the start of drug administration seems necessary 
to prevent these problems.
Some regimens of combination chemotherapy with 
high response rates have been recently reported for ad-
vanced gastric cancer. A 5-FU and low-dose cisplatin Interstitial lung disease caused by TS-1
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(CDDP) regimen is currently used widely due to its high 
efficacy [2], and our patient also received it initially.
Drug-induced ILD is not uncommon, ranging from be-
nign infiltration to life-threatening acute respiratory dis-
tress syndrome. These clinical patterns differ depending on 
the patient’s illness and drug factors, including the type of 
drug [7]. A comprehensive knowledge of the mechanisms 
involved in the development of drug-induced ILD has not 
been achieved. The patient with suspected ILD presents a 
diagnostic challenge to physicians. Clinical, radiologic, and 
pathologic observations are necessary to exclude other con-
ditions with similar symptoms, such as lymphangitis carci-
nomatosis, pneumonia, allergy, cardiogenic edema, and 
pulmonary hemorrhage. Thus, a detailed recent drug his-
tory is helpful to make the diagnosis.
There has been only one report of ILD induced by TS-1 
in patients with gastric cancer [8]. ILD was aggravated af-
ter the start of treatment with TS-1 within 1 month. The 
chemotherapy was discontinued promptly and the patient 
was treated with corticosteroids for 9 days. The subjective 
symptoms improved considerably and the interstitial 
shadows observed on the radiologic evaluations were 
resolved. Thus, the patient who had an acute onset of pul-
monary complications due to TS-1 appeared to have 
recovered.
The patient in the present report had a different course. 
She was treated with TS-1 and low-dose cisplatin for 6 
months, then continued the single-agent use of TS-1 for 8 
months. Cisplatin might not be associated with ILD be-
cause there was no evidence of drug-induced adverse ef-
fects after the termination of combination therapy.
S-1 combines three pharmacological agents: tegafur, 
CDHP, and potassium Oxo. These agents maintains a high 
concentration of 5-FU in the blood and tumors over period 
of time, although plasma level of TS-1 was not checked. 
Urinary excretion within 12 hours after administration of 
TS-1 was 47.4% for CDHP, and 7.0% for 5-FU. Urinary ex-
cretion within 72 hours was 52.8% for CDHP, and 7.4% for 
5-FU. Urinary excretion was nearly completed by 12 hours 
and large amounts of 5-FU excrete as CO2 by lung [9]. 
Therefore, ILD is thought to be caused by a misdirected 
immune or healing reaction to TS-1 for long time. We as-
sumed that long-term retention and reaction of the drug in 
the lung would alter the lung parenchyma irreversibly, 
and might impair resolution on discontinuation of the 
drug with multiple therapies, including the admin-
istration of corticosteroids. Thus, the only method to avoid 
the progression to life-threatening ILD is prevention or 
early detection of disease.
One study showed that interstitial shadows on radio-
logic findings are associated with a risk of ILD in patients 
with such findings [10]. Therefore, we recommended that 
a pulmonary radiologic evaluation should be performed 
before the start of TS-1 for the prevention of ILD. 
Moreover, routine pulmonary evaluation is inevitable in 
patients who are prescribed TS-1 to detect the progression 
of ILD at an early stage, thus providing an opportunity to 
recover and reduce the drug-associated morbidity and 
mortality.
In conclusion, TS-1 is a proven anti-cancer agent for gas-
tric cancer with a high response rate and low toxicity. The 
outpatient use of TS-1 is thus attractive for both physicians 
and patients. Occasionally, TS-1 can cause irreversible ILD 
with a long-term retention in the lung that the outcome 
can be life-threatening. Thus, we have to keep in mind the 
potential for drug toxicity in the form of ILD. Pulmonary 
evaluation by meticulous history taking and physical ex-
amination and chest X-ray is advisable in patients who are 
prescribed TS-1 so that it may contribute to a reduction in 
its morbidity and mortality. We should identity the mech-
anism underlying the fatal complication of TS-1 and clar-
ify which component of the drug is mostly related to it.
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